You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Applying Clinical Data to Advanced Prostate Cancer in the United Kingdom

  • Authors: Heather Payne, MD, FRCP, FRCR; Rob Jones, MD, PhD; Gert Attard, MD, PhD, FRCP
  • CPD Released: 4/28/2022
  • Valid for credit through: 4/28/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hem/onc specialists, urologists, and pathologists.

The goal of this activity is to improve knowledge and confidence of treating physicians within the United Kingdom on the current clinical challenges in the management of advanced prostate cancer and how new data can help address ongoing clinical needs. 

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Latest clinical data for available treatment options in advanced prostate cancer
    • Individualizing treatment after progression in advanced prostate cancer
  • Demonstrate greater confidence in their ability to
    • Manage patients on treatment with advanced prostate cancer


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Faculty

  • Heather Payne, MD, FRCP, FRCR

    Honorary Consultant in Clinical Oncology
    University College Hospital
    London, United Kingdom

    Disclosures

    Grants for clinical research from: Astellas Pharma, Inc.; Janssen-Cilag
    Advisor or consultant for: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Bayer AG; Novartis Advanced Accelerator Applications (AAA); Ferring Pharmaceuticals
    Speaker or member of speakers bureau for: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Bayer AG; Novartis Advanced Accelerator Applications (AAA); Ferring Pharmaceuticals
    Other: Honoraria from: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Aventis Pharmaceuticals Inc.; Bayer AG; Ferring Pharmaceuticals; Janssen-Cilag; Novartis Pharmaceuticals Corporation; Sanofi

  • Rob Jones, MD, PhD

    Professor of Clinical Cancer Research 
    Beatson West of Scotland Cancer Centre ​
    University of Glasgow 
    Glasgow, United Kingdom

    Disclosures

    Grants for clinical research from: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Bayer AG; Clovis Oncology; Exelixis, Inc.; Roche
    Advisor or consultant for: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Bayer AG; Bristol-Myers Squibb Company; Eisai Inc.; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme GmbH; Novartis Advanced Accelerator Applications (AAA); Pfizer Inc.; QED Therapeutics
    Speaker or member of speakers bureau for: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Bayer AG; Bristol-Myers Squibb Company; EMD Serono, Inc.; Ipsen; Janssen-Cilag; Merck Sharp & Dohme GmbH; Pfizer Inc.; Roche

  • Gert Attard, MD, PhD, FRCP

    Professor
    Chair, Urological Cancer Research
    Team Lead, Treatment Resistance Group ​
    UCL Cancer Institute ​
    University College London ​
    London, United Kingdom ​

    Disclosures

    Independent contractor for: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Bayer AG; GU Connect; Ipsen; Janssen-Cilag; Novartis Pharmaceuticals Corporation; Orion Corporation; Pfizer Inc.; Sanofi
    Grants for clinical research from: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Janssen-Cilag
    Advisor or consultant for: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Bayer AG; Ipsen; Janssen-Cilag; Novartis Pharmaceuticals Corporation; Pfizer Inc.
    Speaker or member of speakers bureau for: Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Bayer AG; GU Connect; Ipsen; Janssen-Cilag; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sanofi
    Royalties or patent beneficiary: Janssen

Editors

  • Deborah Grainger, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Deborah Grainger, PhD, has no relevant financial relationships. 

  • Eloise Ballard, PhD

    Scientific Content Manager, WebMD Global, LLC 

    Disclosures

    Disclosure: Eloise Ballard, PhD, has no relevant financial relationships. 

Compliance Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Applying Clinical Data to Advanced Prostate Cancer in the United Kingdom

Authors: Heather Payne, MD, FRCP, FRCR; Rob Jones, MD, PhD; Gert Attard, MD, PhD, FRCPFaculty and Disclosures

CPD Released: 4/28/2022

Valid for credit through: 4/28/2023

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

Treatment of Advanced Prostate Cancer in the United Kingdom​: Current Clinical Challenges

Dr Payne introduces the program, touching on current clinical challenges faced by healthcare professionals caring for patients with advanced prostate cancer.
Heather Payne, MD, FRCP, FRCR

Implications of New Data in Advanced Prostate Cancer for Clinical Practice

Join Dr Jones as he provides a recap of the latest data from key clinical studies across the advanced prostate cancer spectrum.
Rob Jones, MD, PhD

Individualizing Treatment in Advanced Prostate Cancer​: What Do You Need to Consider?

In this section, Dr Attard explains how to leverage the latest clinical data to make more informed treatment decisions for patients with advanced prostate cancer.
Gert Attard, MD, PhD, FRCP

Multidisciplinary Team Management of Patients With Advanced Prostate Cancer

Dr Payne wraps up the program by discussing the role of the multidisciplinary team, plus important considerations for quality-of-life outcomes in patients living with advanced disease.
Heather Payne, MD, FRCP, FRCR
 

Assessment Survey

Before you begin, please take this brief survey.

  • Print